FDA clears Therapixel mammo AI software for tomosynthesis

By AuntMinnie.com staff writers

November 28, 2021 -- French artificial intelligence (AI) software developer Therapixel's MamoScreen software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use with digital breast tomosynthesis.

The software was designed to help radiologists with breast screening by detecting and characterizing suspicious soft-tissue lesions and calcifications. The likelihood of malignancy of lesions is rated on a scale of 1-10.

MammoScreen was cleared for use with traditional 2D screening mammography in July, and the 3D tomosynthesis clearance will broaden its potential use to the whole U.S. mammography market, Therapixel said. The regulatory clearance was supported by a multireader study in which the software boosted performance while also saving reading time; a challenge with tomosynthesis is that the technology produces many images, according to the company.

Copyright © 2021 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking